Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a boy with ectodermal dysplasias who was genetically diagnosed due to newly discovered TSPEAR gene variants, which have now been associated with this condition.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.

This retrospective study in a tertiary hair clinic concluded that routine monitoring of heart rate, weight, liver, and kidney function is not necessary for asymptomatic patients with normal baseline values undergoing low-dose oral minoxidil treatment, although monitoring is advised for those with preexisting renal impairment.

In this multicenter Phase II trial, researchers found that topical GT20029 significantly increased hair regrowth in Chinese adult males with androgenetic alopecia compared to placebo, demonstrating good tolerability and suggesting the need for further studies to confirm its therapeutic potential.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

This study found that transcutaneous electrical acustimulation aided wound healing in mice by enhancing expression of proteins related to signaling pathways, stress recovery, and mitochondrial function.

This study identified a key Arabidopsis thaliana gene, TIP1, whose product is involved in S-acylation crucial for normal plant cell growth, particularly affecting root hair development.

This observational study reviewed thyroid eye disease patients treated with teprotumumab at one center, reporting common side effects like fatigue and dry eye symptoms, with serious adverse events including two cases of blood clots and one pulmonary embolism.

Mutations in the TSPEAR gene cause a new form of ectodermal dysplasia affecting hair and tooth development.

This article provides an overview of mesenchymal stem cells, highlighting their extraction methods, differentiation potential, and applications in regenerative medicine, but reports no new clinical findings.

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

This paper reviews adverse events related to hedgehog pathway inhibitors in advanced basal cell carcinoma patients, reporting no new clinical results but aiming to inform healthcare professionals for improved patient care.

This review examines mesenchymal stem cell therapy as a promising alternative for end-stage liver disease, discussing completed clinical trials and highlighting challenges that must be addressed before clinical application.

This review collected findings on the various cosmetic and therapeutic properties of tea extracts, highlighting their antioxidant, anti-inflammatory, and photoprotective effects among other benefits for skin and hair care.

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

This review discusses the unique advantages and challenges of microneedle arrays for vaccine and immunotherapy delivery but reports no new clinical results.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study found that proxalutamide significantly increased recovery rates, reduced mortality, and shortened hospital stays in hospitalized COVID-19 patients across different regions in Brazil.

VYC-12L effectively improves skin smoothness, reduces fine lines, and boosts hydration.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.